[Corrigendum] miR‑504 promotes tumour growth and metastasis in human osteosarcoma by targeting TP53INP1

Cai,Qingchun; Zeng,Sixiang; Dai,Xing; Wu,Junlong; Ma,Wei

doi:10.3892/or.2025.8914

July-2025 Volume 54 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2025 Volume 54 Issue 1

Full Size Image

Correction Open Access

[Corrigendum] miR‑504 promotes tumour growth and metastasis in human osteosarcoma by targeting TP53INP1

Authors:
- Qingchun Cai
- Sixiang Zeng
- Xing Dai
- Junlong Wu
- Wei Ma
View Affiliations / Copyright

Affiliations: Department of Orthopaedics, First Affiliated Hospital of the Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China

Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 81
|
Published online on: May 14, 2025

https://doi.org/10.3892/or.2025.8914
Expand metrics +

Article

Oncol Rep 38: [Related article:] 2993–3000, 2017; DOI: 10.3892/or.2017.5983

Following the publication of the above article, an interested reader drew to the authors' attention that, concerning the Transwell assay experiments shown in Fig. 2F on p. 2997, the ‘Blank’ and ‘Normal control’ data panels featured a strikingly similar overlapping area, such that these data had apparently been derived from the same original source where the results of differently performed experiments were meant to have been shown.

Figure 2.

miR-504 enhances 143B cell growth and promotes metastasis in vitro by targeting TP53INP1. (A) The Cell Counting Kit-8 assay was performed to evaluate cell proliferation 3–7 days post-transfection. (B) The clone formation assay was performed to examine cell activity at 9 days post-transfection. (C) The cell cycle distribution was determined by flow cytometric analysis with propidium iodide staining. (D) The proportion of apoptotic cells was determined by flow cytometric analysis with Annexin-V and propidium iodide staining. (E) Transwell assay results. The images show the cells that travelled through the micropore membrane without Matrigel. (F) Transwell assay results. The images show the cells that travelled through the micropore membrane with Matrigel. Normal control, 143B cells transfected with the normal control; miR-504 mimic, 143B cells transfected with the miR-504 mimic; miR-504 inhibitor, 143B cells transfected with the miR-504 inhibitor. *P<0.05, **P<0.01 vs. the normal control. All experiments were performed in triplicate. TP53INP1, tumour protein p53-inducible nuclear protein 1.

After having re-examined their original data, the authors realized that Fig. 2F had inadvertently been assembled incorrectly; however, the authors were able to repeat these experiments, and the revised version of Fig. 2, now including new data for the experiments shown in Fig. 2F, is shown on the next page. Note that the errors made in terms of assembling the data in Fig. 2 did not greatly affect either the results or the conclusions reported in this paper, and all the authors agree to the publication of this corrigendum. The authors regret that these errors went unnoticed prior to the publication of their article, and are grateful to the Editor of Oncology Reports for allowing them this opportunity to publish this corrigendum. They also apologize to the readership for any inconvenience caused.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

[Corrigendum] miR‑504 promotes tumour growth and metastasis in human osteosarcoma by targeting TP53INP1

This article is mentioned in:

Article

Figure 2.

Related Articles